Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral doxapram dosing for apnoea of prematurity
ACTRN12621001163897Phase 2Completed
- Sponsor
- The University of Auckland
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxapram in apnea of prematurity (AOP) (2 arms), sponsored by The University of Auckland. Primary endpoint: Proportion of infants with steady state doxapram plasma concentration in the therapeutic range of 1.5 to 4.0 mg/L. Started Feb 2022; status: completed.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on ACTRN12621001163897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001163897.